Compare RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) (RELX) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) vs Smith & Nephew plc — how do they compare? RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) trades at $36.73 (market cap $63.57B), while Smith & Nephew plc trades at $27.9 (market cap $11.60B). The key difference: RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) is far larger — about 5.5× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.85%). Which is the better fit depends on your goals.
| RELX | SNN | |
|---|---|---|
Market Cap | $63.57B | $11.60B |
Volume | 1,602,093 | 971,836 |
Sector | Industrials | Health |
52-Week High | $46.80 | $37.17 |
52-Week Low | $27.73 | $26.42 |
Enterprise Value | $75.05B | $14.63B |
Dividend Yield | 2.49% | 2.85% |
Typical Hold Time | — | 121 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RELX trades at $36.70, up 0.44% with neutral technical signals. The company demonstrates strong profitability with 23.27% net margins and 132.36% ROE, though valuation metrics appear elevated with P/E of 22.21 and P/B of 38.89. Recent earnings show mixed results with Q2 2026 beating expectations while Q4 2025 missed. Analyst sentiment remains positive with 71% buy ratings and consensus price target of $26.00.
The investment case balances strong fundamentals against premium valuation. Growth catalysts include AI-driven product adoption and margin expansion, while risks involve competitive pressures and valuation concerns. With solid cash flow generation and institutional support, RELX offers quality exposure but requires monitoring of valuation multiples and competitive dynamics.
SNN trades at $27.88, near its 52-week low, with a mixed technical signal but improving fundamentals. Revenue grew to $6.16B in 2025, with net income margin expanding to 10.08%. Recent product launches like the EVOS PELVIC System and FLOW FLEXTEND COBLATION Wand highlight innovation, though the stock faces bearish moving averages and neutral oscillators.
Outlook is cautious; strong profitability and cash flow support value, but analyst consensus is predominantly Hold amid competitive pressures and recent CFO departure. Risks include execution challenges and debt levels, yet institutional interest from BlackRock's $505M investment signals confidence. The stock offers potential for recovery if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share)
RELX PLC is a UK-based information and analytics company operating across four segments: Risk (fraud prevention and compliance analytics via LexisNexis Risk Solutions), Scientific, Technical & Medical (Elsevier's research and clinical content), Legal (LexisNexis Legal & Professional's research tools), and Exhibitions (RX's trade events). It serves professional, business, and government customers worldwide.
Read more on RELX →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
